TargetBeta
TAAR1
trace amine associated receptor 1 · also TAR1, TA1, TRAR1 · Trace amine receptors
2 programs in company-led studies act on TAAR1, from 2 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
Also acted on by the same programs
Conditions their studies are in
- Alcoholism, 1 program
- Depressive Disorder, Major, 1 program
- Generalized Anxiety Disorder, 1 program
- Narcolepsy, 1 program
- Parkinson Disease, 1 program
- Schizophrenia, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 2027NTX-2001 · Newleos Therapeutics · phase 1 · NCT07520292
- Mar 2028ulotaront · Otsuka · phase 3 · NCT07225712
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.